MedTrace Logo

Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

NCT03956524 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of EuTCV, in comparison to TCV (Typbar-TCV™, Bharat Biotech) and Vi-Polysaccharide vaccine (Typhim Vi®, Sanofi Pasteur) in healthy adult volunteers.

Conditions

  • Typhoid Fever

Interventions

BIOLOGICAL

EuTCV

Single 0.5 mL dose of TCV of EuBiologics co., Ltd.

BIOLOGICAL

Typbar-TCV™

Single 0.5 mL dose of TCV of Bharat Biotech

BIOLOGICAL

Typhim Vi®

Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur

Sponsors & Collaborators

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-16
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956524 on ClinicalTrials.gov